GlassScriptPhysician profile
Douglas Russell
NPI 1912343096
$3,278.83
in general payments reported to CMS, 2019-2025
32 companies · $253 in 2025
The $253 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $372 · 2021: $339 · 2022: $691 · 2023: $332 · 2024: $416 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $916 · Education: $85.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $915.66 |
| Education | $85.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $635.31 | 2019-2024 | Xtandi, Myrbetriq |
| Janssen Biotech, INC. | $281.52 | 2019-2021 | |
| Neotract INC. | $237.70 | 2019-2020 | |
| Procept Biorobotics Corporation | $223.94 | 2022-2025 | Aquabeam System |
| Boston Scientific Corporation | $221.91 | 2019 | |
| Pfizer INC. | $176.48 | 2019-2023 | |
| Teleflex LLC | $159.94 | 2021-2022 | |
| Axonics, INC. | $131.66 | 2023 | Axonics |
| Novartis Pharmaceuticals Corporation | $114.63 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.20 | 2020-2025 | |
| Abbvie INC. | $98.43 | 2023-2025 | Botox |
| Olympus America INC. | $91.16 | 2025 | Itind System |
| Sun Pharmaceutical Industries INC. | $87.57 | 2022-2024 | |
| Dendreon Pharmaceuticals LLC | $78.63 | 2019-2023 | Provenge |
| Merck Sharp & Dohme LLC | $68.56 | 2021-2024 | Lynparza |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $66.41 | 2019-2024 | Adstiladrin |
| Endo Pharmaceuticals INC. | $64.05 | 2019-2023 | Xiaflex, Aveed |
| Allergan, INC. | $57.13 | 2019 | |
| Blue Earth Diagnostics | $55.35 | 2019-2023 | |
| Tolmar Pharmaceuticals, INC. | $51.46 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $40.57 | 2023-2024 | Gemtesa |
| Urovant Sciences INC | $28.82 | 2022 | |
| Clarus Therapeutics INC. | $27.26 | 2021 | |
| Myriad Genetic Laboratories, INC. | $26.91 | 2024 | Prolaris |
| Amgen INC. | $23.97 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $21.87 | 2022 | |
| Tolmar, INC. | $19.78 | 2025 | Jatenzo, Eligard |
| Conmed Corporation | $18.90 | 2019 | |
| Antares Pharma, INC. | $18.75 | 2022 | |
| Urogen Pharma, INC. | $18.70 | 2024 | |
| Avadel Specialty Pharmaceuticals, LLC | $16.60 | 2019 | |
| Melinta Therapeutics, LLC | $15.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Russell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.